Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398933 | 1.00 | HTT (0.52) | HTTNAALAD2CTSSMEN1KMT2A | |
| SCHEMBL1398932 | 1.00 | HTT (0.52) | HTTNAALAD2CTSSMEN1KMT2A | |
| SCHEMBL2963801 | 0.87 | CTSS (0.52) | HTTCTSSMEN1KMT2AITGB3 | |
| SCHEMBL3584842 | 0.87 | CTSS (0.52) | HTTCTSSMEN1KMT2AITGB3 | |
| SCHEMBL6707580 | 0.87 | CTSS (0.47) | HTTCTSSMEN1KMT2AITGB3 | |
| SCHEMBL27517608 | 0.87 | MEN1 (0.49) | HTTCTSSMEN1KMT2AITGB3 | |
| SCHEMBL9087628 | 0.86 | HTT (0.52) | HTTCTSSMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2777369 | 0.86 | HTT (0.52) | HTTCTSSMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1198965 | 0.86 | CTSS (0.53) | HTTCTSSMEN1KMT2AITGB3 | |
| SCHEMBL8700050 | 0.86 | HTT (0.55) | HTTCTSSMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20160339006-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-9376424-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| WO-2008034032-A2 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1868434-A2 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | Azevan Pharmaceuticals, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007109615-A2 | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006102283-A2 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | HTT 1042/4885NAALAD2 1577/4885CTSS 150/4885 |
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | HTT 1298/4885NAALAD2 1522/4885CTSS 568/4885 |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | HTT 1/4885NAALAD2 1963/4885CTSS 505/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | HTT 1298/4885NAALAD2 1522/4885CTSS 568/4885 |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, FAAH2 | HTT 2636/4885NAALAD2 217/4885CTSS 2582/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | HTT 1042/4885NAALAD2 1577/4885CTSS 150/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | HTT 3768/4885NAALAD2 166/4885CTSS 2586/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | HTT 1/4885NAALAD2 1963/4885CTSS 505/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | HTT 1/4885NAALAD2 1963/4885CTSS 505/4885 |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | HTT 1/4885NAALAD2 1963/4885CTSS 505/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | HTT 1042/4885NAALAD2 1577/4885CTSS 150/4885 |
| US-20130109666-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | HTT 1298/4885NAALAD2 1522/4885CTSS 568/4885 |
| US-20160339006-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | HTT 1298/4885NAALAD2 1522/4885CTSS 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.